Oncotarget

Research Papers:

Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors

Xiao-jun Qian _, Yun-tian Li, Yan Yu, Fen Yang, Rong Deng, Ji Ji, Lin Jiao, Xuan Li, Rui-Yan Wu, Wen-Dan Chen, Gong-Kan Feng and Xiao-Feng Zhu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:5134-5146. https://doi.org/10.18632/oncotarget.3016

Metrics: PDF 2331 views  |   HTML 1814 views  |   ?  


Abstract

Xiao-jun Qian1,2,*, Yun-tian Li1,*, Yan Yu1,*, Fen Yang1,3, Rong Deng1, Jiao Ji1, Lin Jiao1, Xuan Li1, Rui-Yan Wu1, Wen-Dan Chen1, Gong-Kan Feng1, Xiao-Feng Zhu1

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China

2Department of Oncology, Anhui Provincial Hospital, Affiliated to Anhui Medical University, Hefei 230001, China

3Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing 210000, China

*These authors have contributed equally to this work

Correspondence to:

Xiao-Feng Zhu, e-mail: zhuxfeng@mail.sysu.edu.cn

Keywords: BEZ235, Acquired Resistance, DNA Methyltransferase, Nasopharyngeal Carcinoma

Received: November 26, 2014     Accepted: December 31, 2014     Published: February 11, 2015

ABSTRACT

Dual PI3K/mTOR(phosphatidylinositol 3-kinase/mammalian target of rapamycin) inhibitors are being evaluated clinically for the treatment of tumors with a hyperactivated PI3K/mTOR pathway. However, unexpected outcomes were obtained in clinical studies of cancer patients with an aberrant PI3K pathway. In clinical trials, applicable combination regimens are not yet available. In this study, using an integrated analysis of acquired BEZ235-resistant nasopharyngeal carcinoma cells, we demonstrate that DNA methyltransferase is a key modulator and a common node upstream of the AKT/mTOR and PDK1/MYC pathways, which are activated in cancer cells with acquired BEZ235 resistance. DNA methyltransferases were upregulated and induced PTEN and PPP2R2B gene hypermethylation, which downregulated their expression in BEZ235-resistant cancer cells. Reduced PTEN and PPP2R2B expression correlated with activated AKT/mTOR and PDK1/MYC pathways and conferred considerable BEZ235 resistance in nasopharyngeal carcinoma. Targeting methyltransferases in combination with BEZ235 sensitized BEZ235-resistant cells to BEZ235 in vitro and in vivo, suggesting the potential clinical application of this strategy to overcome BEZ235 resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3016